132 related articles for article (PubMed ID: 32762473)
1. Germline
Park HS; Son BR; Shin KS; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Leuk Lymphoma; 2020 Dec; 61(13):3251-3254. PubMed ID: 32762473
[No Abstract] [Full Text] [Related]
2. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
3. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
Bench AJ; White HE; Foroni L; Godfrey AL; Gerrard G; Akiki S; Awan A; Carter I; Goday-Fernandez A; Langabeer SE; Clench T; Clark J; Evans PA; Grimwade D; Schuh A; McMullin MF; Green AR; Harrison CN; Cross NC;
Br J Haematol; 2013 Jan; 160(1):25-34. PubMed ID: 23057517
[TBL] [Abstract][Full Text] [Related]
4. JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Girsberger S; Karow A; Lundberg P; Dirnhofer S; Lehmann T; Passweg JR; Tichelli A; Skoda R; Rovó A
Acta Haematol; 2013; 129(1):23-5. PubMed ID: 23006959
[No Abstract] [Full Text] [Related]
5. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
6. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
Cazzola M; Kralovics R
Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775
[TBL] [Abstract][Full Text] [Related]
7. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
Malysz J; Crisan D
Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
[TBL] [Abstract][Full Text] [Related]
8. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
10. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
11. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
12. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.
Brooks SA; Luty SB; Lai HY; Morse SJ; Nguyen TK; Royer LR; Agarwal A; Druker BJ; Fleischman AG
Exp Hematol; 2016 Jan; 44(1):24-9.e1. PubMed ID: 26458983
[TBL] [Abstract][Full Text] [Related]
13. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
14. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
15. A myeloproliferative neoplasm with translocation t(8;9)(p22;p24) involving JAK2 gene.
Saba N; Safah H
Blood; 2013 Aug; 122(6):861. PubMed ID: 24079014
[No Abstract] [Full Text] [Related]
16. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
[TBL] [Abstract][Full Text] [Related]
17. [Biological characteristics of bone marrow mesenchymal stem cells and JAK2 mutation in myeloproliferative neoplasms].
Tian H; Chen GH; Xu Y; Wang RX; Qiao M; Liu HW; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):701-4. PubMed ID: 23336220
[TBL] [Abstract][Full Text] [Related]
18. Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.
Collier P; Patel K; Waeltz P; Rupar M; Luthra R; Liu PC; Hollis G; Huber R; Verstovsek S; Burn TC
Genet Test Mol Biomarkers; 2013 May; 17(5):429-37. PubMed ID: 23537216
[TBL] [Abstract][Full Text] [Related]
19. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
20. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
